Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism.

Pollak Y, Mechlovich D, Amit T, Bar-Am O, Manov I, Mandel SA, Weinreb O, Meyron-Holtz EG, Iancu TC, Youdim MB.

J Neural Transm. 2013 Jan;120(1):37-48. doi: 10.1007/s00702-012-0795-x. Epub 2012 Mar 25.

PMID:
22446839
[PubMed - indexed for MEDLINE]
2.
3.

The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage.

Mechlovich D, Amit T, Mandel SA, Bar-Am O, Bloch K, Vardi P, Youdim MB.

J Pharmacol Exp Ther. 2010 Jun;333(3):874-82. doi: 10.1124/jpet.109.164269. Epub 2010 Mar 17.

PMID:
20237072
[PubMed - indexed for MEDLINE]
Free Article
4.

Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice.

Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O.

Mech Ageing Dev. 2012 May;133(5):267-74. doi: 10.1016/j.mad.2012.03.001. Epub 2012 Mar 10.

PMID:
22426424
[PubMed - indexed for MEDLINE]
5.
7.

Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.

Kupershmidt L, Amit T, Bar-Am O, Weinreb O, Youdim MB.

Mol Neurobiol. 2012 Aug;46(1):217-20. doi: 10.1007/s12035-012-8304-7. Epub 2012 Jul 31.

PMID:
22847630
[PubMed - indexed for MEDLINE]
8.

The novel multi-target iron chelator, M30 modulates HIF-1α-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice.

Mechlovich D, Amit T, Bar-Am O, Mandel S, Youdim MB, Weinreb O.

Curr Alzheimer Res. 2014 Feb;11(2):119-27.

PMID:
24359498
[PubMed - in process]
9.

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.

Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB.

J Neurochem. 2007 Jan;100(2):490-502. Epub 2006 Nov 27.

PMID:
17144902
[PubMed - indexed for MEDLINE]
10.

Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain.

Kupershmidt L, Weinreb O, Amit T, Mandel S, Bar-Am O, Youdim MB.

Neuroscience. 2011 Aug 25;189:345-58. doi: 10.1016/j.neuroscience.2011.03.040. Epub 2011 May 6.

PMID:
21570450
[PubMed - indexed for MEDLINE]
11.

Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30.

Avramovich-Tirosh Y, Bar-Am O, Amit T, Youdim MB, Weinreb O.

Curr Alzheimer Res. 2010 Jun;7(4):300-6.

PMID:
20043814
[PubMed - indexed for MEDLINE]
12.

The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

Youdim MB.

Curr Alzheimer Res. 2006 Dec;3(5):541-50. Review.

PMID:
17168653
[PubMed - indexed for MEDLINE]
13.

From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.

Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, Mandel SA.

J Alzheimers Dis. 2012;30(1):1-16. doi: 10.3233/JAD-2012-120013. Review.

PMID:
22387411
[PubMed - indexed for MEDLINE]
14.

Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.

Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB.

FASEB J. 2009 Nov;23(11):3766-79. doi: 10.1096/fj.09-130047. Epub 2009 Jul 28.

PMID:
19638399
[PubMed - indexed for MEDLINE]
Free Article
15.

Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Weinreb O, Mandel S, Bar-Am O, Amit T.

J Neural Transm. 2011 Mar;118(3):479-92. doi: 10.1007/s00702-011-0597-6. Epub 2011 Mar 1. Review.

PMID:
21360301
[PubMed - indexed for MEDLINE]
16.

Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.

Youdim MB.

Exp Neurobiol. 2013 Mar;22(1):1-10. doi: 10.5607/en.2013.22.1.1. Epub 2013 Mar 31.

PMID:
23585716
[PubMed]
Free PMC Article
17.

M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.

Gal S, Fridkin M, Amit T, Zheng H, Youdim MB.

J Neural Transm Suppl. 2006;(70):447-56.

PMID:
17017567
[PubMed - indexed for MEDLINE]
18.

Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.

Youdim MB, Fridkin M, Zheng H.

J Neural Transm. 2004 Oct;111(10-11):1455-71. Epub 2004 Apr 20.

PMID:
15480846
[PubMed - indexed for MEDLINE]
19.

Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.

Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, Youdim MB.

Neurotherapeutics. 2009 Jan;6(1):163-74. doi: 10.1016/j.nurt.2008.10.030. Review.

PMID:
19110207
[PubMed - indexed for MEDLINE]
20.

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats.

Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB.

Neuropharmacology. 2004 Feb;46(2):254-63.

PMID:
14680763
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk